You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾(688185.SH):重組三價脊髓灰質炎疫苗(Sf-RVN細胞)獲得藥物臨牀試驗批準通知書

格隆匯7月16日丨康希諾(688185.SH)公佈,公司於近日收到國家藥品監督管理局覈準簽發的關於重組三價脊髓灰質炎疫苗(Sf-RVN細胞)(稱“重組脊髓灰質炎疫苗”)的《藥物臨牀試驗批準通知書》。

公司的重組脊髓灰質炎疫苗通過蛋白結構設計和VLP組裝技術製備而成,不含病毒遺傳物質,在生產及檢測過程中不依賴活病毒,預期具有良好的安全性和免疫原性。非傳染性的VLP技術路線脊髓灰質炎疫苗被世界衛生組織推薦作爲未來消滅脊髓灰質炎的首選疫苗之一,有望爲全球根除脊髓灰質炎作出貢獻。該款疫苗正於印度尼西亞開展I/II期臨牀試驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account